Last reviewed · How we verify

NCT04447599: EVACORMA

Conjunctival and Retinal Vascularization and Small Vessel Disease

Status unknown NA Last updated 31 August 2021
What this trial tests

NA trial testing photography of conjunctival vessels in Cerebral Stroke in 850 participants. Status unknown.

Timeline
20 October 2020
Primary endpoint
20 October 2022
20 October 2022

Quick facts

Lead sponsorUniversity Hospital, Toulouse
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment850
Start date20 October 2020
Primary completion20 October 2022
Estimated completion20 October 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

Adults 55 to 80, any sex, with Cerebral Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to use a simple photography of conjunctival vessels to search for an association between conjunctival vessels abnormalities and the load of small vessel disease as quantified by MRI in patients with TIA s and minor strokes. The artificial intelligence (AI) tools will permit to classify abnormalities of conjunctival vessels that predict the load of small vessel disease in TIAs and strokes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cerebral Stroke

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04447599.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing